drugset / Trial / NCT04864977

A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

NCT04864977

Phase 4 Withdrawn Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate a novel approach for insulin glargine (LY2963016) titration for insulin-naïve adults with type 2 diabetes (T2D) The study will last about 6 months.

Timeline

Start
2021-08-16
Primary completion
2022-06-06
Completion
2022-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic Subcutaneous